Tilray Brands applauds the U.S. federal government's rescheduling of cannabis from Schedule I to Schedule III, a major policy shift enabling expanded medical cannabis research and patient access. This change is expected to accelerate clinical studies, improve safety standards, and broaden availability for patients with conditions like cancer, chronic pain, PTSD, and epilepsy. Tilray, with its extensive global cultivation and pharmaceutical-grade production, is well-positioned to lead the emerging regulated medical cannabis market in the U.S., including potential participation in a Medicare pilot program to supply hemp-derived medical cannabis to vulnerable patients.
The cannabis industry is expanding rapidly with cannabis now classified as a Class 3 substance, reducing legal barriers for operators. This shift allows for more research, product development, and growth opportunities for both cannabis producers and ...
Tilray Brands, a global leader in cannabis and consumer packaged goods, will announce its financial results for the fourth quarter and full fiscal year ending May 31, 2026, on July 28, 2026, after market close. The company will hold a live conference...
BrewDog Waterloo, England's largest pub owned by Tilray Brands, is set to host a major watch party for the England vs Argentina semifinal. The event promises an electric atmosphere with giant screens and passionate fans. Tilray's £1 million bar tab p...
